Fiserv stock plunged over 16% despite beating Q2 earnings expectations, as the company lowered its full-year organic revenue ...

AT&T's second-quarter results have exceeded expectations, driven by robust growth in 5G and fiber subscribers.

GM beat Q2 2025 earnings expectations but shares fell 7% due to $1.1 billion tariff impact and margin compression concerns.

Boston Scientific's Q2 2025 results exceeded expectations, with net sales of $5.061 billion and adjusted EPS of $0.75.

Thermo Fisher Scientific's second quarter of 2025 demonstrated a 3% revenue increase to $10.85 billion, slightly surpassing expectations.

Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug ...